GI Innovation

With the state-run Korea Drug Development Fund (KDDF), which plays a key role in providing R&D support to the country’s biopharma industry, already midway through its current 10-year term, the fun

Sentiment around initial public offerings (IPOs) appears to be slowly recovering in South Korea as the market stabilizes somewhat amid ongoing political uncertainties at home and abroad. A couple of b

With the launch of novel lung cancer drug Leclaza (lazertinib) in South Korea and other international approvals in sight, Yuhan Corporation is at the starting point of potentially evolving into a co

South Korean bioventures have experienced a harsh financing environment in 2023 stemming from economic depression, high interest rates and a general deterioration in investor sentiment. Although most